Project Grant R01HL169242
Award Date
8/21/24
Completion Date
5/31/29
Dollars Obligated
$2M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45229, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,123,357.00 to support research on the bone marrow microenvironment and its role in regulating blood cell production. The research, to be conducted by the Children's Hospital Medical Center in Cincinnati, Ohio, aims to define the spatial organization and specialized vascular microenvironments within the bone marrow that recruit and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $773,257 to St. Jude Children's Research Hospital Inc. to investigate the mechanisms of lysosome segregation and cell fate regulation in dividing hematopoietic stem cells (HSCs). The research aims to identify factors regulating lysosome segregation during HSC division and how this process influences HSC self-renewal and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $435,804 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Childrens Hospital Medical Center in Cincinnati, Ohio. The grant will fund research to elucidate the mechanistic basis for the selective advantage of the acquired DDX41R525H mutation in hematopoietic stem cells (HSCs) of patients with germline DDX41 mutations, who develop myelodysplastic syndrome (MDS) and related myeloid malignancies. The...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $169,156 to The Washington University in St. Louis to support a 5-year research program focused on optimizing hematopoietic stem cell transplantation (HSCT) to treat non-malignant diseases, particularly sickle cell disease (SCD). The key objectives are to: 1) Evaluate novel stem cell mobilization regimens combining VLA-4 and CXCR4 inhibition to generate...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $561,030 to the Children's Research Institute to study the impact of CD52 knockout on the function of multi-virus-specific T cells. The goal is to determine if CD52 knockout can enable T cell persistence and efficacy in the presence of the immunosuppressive drug alemtuzumab. Key activities include optimizing CRISPR/Cas9 editing of virus-specific T cells,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $153,117 to support a 5-year research project focused on improving hematopoietic stem cell (HSPC) transplantation outcomes. The goal is to investigate mechanisms of HSPC-niche cell crosstalk, specifically how HSPC-derived extracellular vesicles promote remodeling of bone marrow endothelial cells and migration of HSPCs. The...
This K23 career development award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $321,036 over the period of Aug 15, 2024 to Jul 31, 2029 to the Children's Research Institute in Washington, D.C. The goal of this project is to develop the candidate into an independent investigator in the field of immune modulatory cell therapy for critically ill children, particularly those post hematopoietic stem cell transplant. The specific aims are...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $739,236 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Childrens Hospital Medical Center in Cincinnati, OH. The grant supports research to elucidate the cellular mechanisms underlying sirolimus insensitivity in lymphangioleiomyomatosis (LAM), a rare and destructive lung disease. Key objectives include identifying molecular determinants of sirolimus insensitivity, evaluating the role of YAP-WNT pathways, and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $180,199 to the Research Institute at Nationwide Children's Hospital in Columbus, Ohio. The objective is to identify myeloid-derived suppressor cells (MDSC) as contributors to the immune response in children with viral lower respiratory tract infections (LRTI) and to investigate the PD-1 pathway as a potential therapeutic...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $146,876 to the Coriell Institute for Medical Research to develop new methods for expanding functional hematopoietic stem cells (HSCs) from cryopreserved umbilical cord blood (UCB) samples. The project aims to optimize an approach using PPAR-α agonists, which have been shown to significantly expand long-term functional UCB HSCs...